Netzealous LLC DBA - Compliance4All, Online
2018-02-28
Overview: This webinar will be helpful to applicants conducting BA/BE studies
during the IND period, also FDA guidance recommendations on how to
meet the BA and BE requirements in 21 CFR 320 as they apply to oral
dosage forms.
Why should you Attend: Understanding when Bioavailability and Bioequivalence studies should
be done can help attendees avoid having to re-do clinical trials, help to
determine dosage regimen that achieves target drug exposure.
Areas Covered in the Session:
Review definitions necessary for understanding bioavailability and
bioequivalence Review of FDA guidance recommendations on how to meet the BA and
BE requirements in 21 CFR 320 as they apply to oral dosage forms. This webinar will be helpful to applicants conducting BA/BE studies
during the IND period.
Who Will Benefit: Regulatory Managers Specialists R&D Production Personnel Quality Clinical Personnel Laboratory Personnel
Event Fee: One Dial-in One Attendee Price: US$150.00
Contact Detail: Compliance4All DBA NetZealous, Phone: +1-800-447-9407 Email: support@compliance4All.com
|